Gao et al. studied drug response in seven new human prostate cancer organoid lines derived from metastatic and circulating tumour cells expressing disease-specific mutations such as TMPRSS2-ERG fusion, PTEN loss, TP53 loss, SPOP mutations, FOXA1 mutations and CHD1 loss [55]. This evidence concerns the gene ERG and prostate cancer.